# Oxaliplatin in Rectal Cancer

> **NCT00259363** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 46 (actual)

## Conditions studied

- Rectal Neoplasms

## Interventions

- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00259363
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-10
- **Primary completion:** 2006-06
- **Final completion:** —
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Study cancelled because recruitment rate was too slow
- **Last updated:** 2009-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00259363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00259363, "Oxaliplatin in Rectal Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00259363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*